Ontology highlight
ABSTRACT:
SUBMITTER: Spencer HT
PROVIDER: S-EPMC3034847 | biostudies-other | 2011 Feb
REPOSITORIES: biostudies-other
Spencer H Trent HT Denning Gabriela G Gautney Richard E RE Dropulic Boro B Roy Andre J AJ Baranyi Lajos L Gangadharan Bagirath B Parker Ernest T ET Lollar Pete P Doering Christopher B CB
Molecular therapy : the journal of the American Society of Gene Therapy 20101116 2
Patients with hemophilia A present with spontaneous and sometimes life-threatening bleeding episodes that are treated using blood coagulation factor VIII (fVIII) replacement products. Although effective, these products have limited availability worldwide due to supply limitations and product costs, which stem largely from manufacturing complexity. Current mammalian cell culture manufacturing systems yield around 100 µg/l of recombinant fVIII, with a per cell production rate of 0.05 pg/cell/day, ...[more]